Ad-KDRscFv:sTRAIL displays a synergistic antitumor effect without obvious cytotoxicity to normal tissues

International Immunopharmacology

Volumn 13, Issue 1, 2012, Pages 37-45

  Yang, Liuqin ^a   Guo, Jun ^a   Wang, Jun ^a   Wan, Shunmei ^a   Yang, Shiming ^a   Wang, Rongquan ^a   Chen, Wensheng ^a   Peng, Guiyong ^a   Fang, Dianchun ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Gene fusion; KDRscFv; Recombinant adenovirus; Replication defective; TRAIL

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CELL STRAIN HEPG2; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG SAFETY; FUSION GENE; GENE CONSTRUCT; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; LIVER; LIVER CANCER; LIVER CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR CELL CULTURE; TUMOR GROWTH; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE; VIRUS PLAQUE; VIRUS RECOMBINANT;

ADENOVIRUSES, HUMAN; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL SURVIVAL; GENE THERAPY; GENETIC VECTORS; HEK293 CELLS; HEP G2 CELLS; HUMANS; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSDUCTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859142312     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2012.02.006     Document Type: Article

References (35)

1. S.R. Wiley, K. Schooley, P.J. Smolak, W.S. Din, C.-P. Huang, and J.K. Nicholl Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 3 1995 673 682
2. H. Wajant, D. Moosmayer, T. Wüest, T. Bartke, E. Gerlach, and U. Schönherr Differential activation of TRAIL-R1 and - 2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative Oncogene 20 2001 4101 4106
3. C. Tecchio, V. Huber, P. Scapini, F. Calzetti, D. Margotto, and G. Todeschini IFNa-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells Blood 103 2004 3837 3844
4. D. Lawrence, Z. Shahrokh, S. Marsters, K. Achilles, D. Shih, and B. Mounho Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions Nat Med 7 2001 383 385
5. S. Armeanu, U.M. Lauer, I. Smirnow, M. Schenk, T.S. Weiss, and M. Gregor Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes Cancer Res 63 2003 2369 2372
6. B. Mundt, F. Kühnel, L. Zender, Y. Paul, H. Tillmann, and C. Trautwein Involvement of TRAIL and its receptors in viral hepatitis FASEB J 17 2003 94 96
7. H. Higuchi, S.F. Bronk, Y. Takikawa, N. Werneburg, R. Takimoto, and W. El-Deiry The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis J Biol Chem 276 2001 38610 38618
8. H. Higuchi, S.F. Bronk, M. Taniai, A. Canbay, and G.J. Gores Cholestasis increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity J Pharmacol Exp Ther 303 2002 461 467
9. K. Takeda, J. Stagg, H. Yagita, K. Okumura, and M.J. Smyth Targeting death-inducing receptor in cancer therapy Oncogene 26 25 2007 3745 3757
10. S.W. Lowe, E. Cepero, and G. Evan Intrinsic tumor suppression Nature 432 2004 307 315
11. M. Jo, T.-H. Kim, D.-W. Seol, J.E. Esplen, K. Dorko, and T.R. Billiar Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand Nat Med 6 2000 564 567
12. R. Di Pietro, M.A. Mariggiò, S. Guarnieri, S. Sancilio, A. Giardinelli, and S. Di Silvestre Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) regulates endothelial nitric oxide synthase (eNOS) activity and its localization within the human vein endothelial cells (HUVEC) in culture J Cell Biochem 97 2006 782 794
13. G. Cantarella, N. Risuglia, R. Dell'eva, L. Lempereur, A. Albini, and G. Pennisi TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells Br J Cancer 94 2006 1428 1435
14. M.A. Hall, and J.L. Cleveland Clearing the TRAIL for cancer therapy Cancer Cell 12 2007 4 6
15. N. Ozoren, K. Kim, T.F. Burns, D.T. Dicker, A.D. Moscioni, and W.S. E1-Deiry The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand Cancer Res 60 22 2000 6259 6265
16. P. Shi-Jun Zheng, G.T. Wang, and Y.H. Chen Critical roles of TRAIL in hepatic cell death and hepatic inflammation J Clin Invest 113 2004 58 64
17. O. Meurette, A. Rebillard, L. Huc, G. Le Moigne, D. Merino, and O. Micheau TRAIL induces receptor-interacting protein 1-dependent and caspase-dependent necrosis-like cell death under acidic extracellular conditions Cancer Res 67 2007 218 226
18. M. Jo, T.-H. Kim, D.-W. Seol, E. James, K.D. Esplen, and T.R. Billiar Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand Nat Med 6 2000 564 567
19. R. Koschny, H. Walczak, and T.M. Ganten The promise of TRAIL - potential and risks of a novel anticancer therapy J Mol Med (Berl) 85 9 2007 923 935
20. J. Held, and K. Schulze-Osthoff Potential and caveats of TRAIL in cancer therapy Drug Resist Updat 4 2001 243 252
21. R.K. Srivastava TRAIL/Apo-2L: mechanisms and clinical applications in cancer Neoplasia 3 2001 535 546
22. H. Higuchi, J.-H. Yoon, A. Grambihler, N. Werneburg, S.F. Bronk, and G.J. Gores Bile acids stimulate cFLIP phosphorylation enhancing TRAIL-mediated apoptosis J Biol Chem 278 2003 454 461
23. D.A. Sallman, X. Chen, B. Zhong, D.L. Gilvary, J. Zhou, and S. Wei Clusterin mediates TRAIL resistance in prostate tumor cells Mol Cancer Ther 6 2007 2938 2947
24. L.-Q. Yang, D.-C. Fang, R.-Q. Wang, and S.-M. Yang Effect of NF-KB, surviving, Bcl-2 and caspase 3 on apoptosis of gastric cancer cells induced by tumor necrosis factor related apoptosis inducing ligand World J Gastroenterol 10 2004 22 26
25. Y. Jiang, K. Chen, Z. Tang, Z. Zeng, W. Yao, and D. Sun TRAIL gene reorganizes the cytoskeleton and decreases the motility of human leukemic Jurkat cells Cell Motil Cytoskeleton 63 2006 471 482
26. H. Van Cruijsen, G. Giaccone, and K. Hoekman Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer strategies Int J Cancer 117 2005 883 888
27. I.K. Dev, R.E. Dornsife, T.M. Hopper, J.A. Onori, C.G. Miller, and L.E. Harrington Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models Br J Cancer 91 2004 1391 1398
28. Z. Zhu, K. Hattori, H. Zhang, X. Jimenez, D.L. Ludwig, and S. Dias Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2: correlation between antibody affinity and biological activity Leukemia 17 2003 604 611
29. T. Karashima, K. Inoue, S. Fukata, T. Iiyama, A. Kurabayashi, and C. Kawada Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice Int J Oncol 30 2007 937 945
30. O. Casanovas, D.J. Hicklin, G. Bergers, and D. Hanahan Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 2005 299 309
31. B. Kou, Y. Li, Y. Shi, J. Xia, X. Wang, and S. Wu Gene therapeutic exploration: retrovirus-mediated soluble vascular endothelial growth factor receptor-2 (sFLK-1) inhibits the tumorigenicity of S180, MCF-7, and B16 cells in vivo Oncol Res 15 2005 239 247
32. J.A. Posey, T.C. Ng, B. Yang, M.B. Khazaeli, M.D. Carpenter, and F. Fox A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma Clin Cancer Res 9 2003 1323 1332
33. N. Weidner, J. Folkman, F. Pozza, P. Bevilacqua, E.N. Allred, and D.H. Moore Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma Natl Cancer Inst 84 1992 1875 1887
34. C. Hao, J.H. Song, B. Hsi, J. Lewis, D.K. Song, and K.C. Petruk TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice Cancer Res 64 2004 8502 8506
35. T.C. He, S. Zhou, L.T. da Costa, J. Yu, K.W. Kinzler, and B. Vogelstein A simplified system for generating recombinant adenoviruses Proc Natl Acad Sci U S A 95 1998 2509 2514